Maverick Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Maverick Capital’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,310,530	Closed	-$26.4M	–	672
2021 Q3	$26.4M	Buy	1,310,530 +2,454	+0.2%	+$67.8K	0.27%	60
2021 Q2	$48.8M	Sell	1,308,076 -44,726	-3%	-$1.37M	0.46%	40
2021 Q1	$34.6M	Buy	+1,352,802	New	+$34.6M	0.32%	43

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Maverick Capital's DRNA Position: Q4 2021 in Review

Maverick Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 1,310,530 shares — an estimated $26.4M sold.

Maverick Capital first reported a position in DRNA in Q1 2021 and held it in 3 quarters. The position peaked at $48.8M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Maverick Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Maverick Capital sold 1,310,530 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $26.4M.
Maverick Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2021 and held it in 3 quarters.
Maverick Capital's Dicerna Pharmaceuticals, Inc. position peaked at $48.8M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.